Patients ( n = 162 ) with persistent/recurrent or de novo Cushing 's disease and urinary free cortisol ( UFC ) levels 15 upper limit of normal ( ULN ) were randomized to receive subcutaneous pasireotide ( 600/900 g bid ) .